Dr. Kluger on Immunotherapy in Melanoma

Harriet Kluger, MD
Published: Friday, Nov 15, 2013

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the effectiveness of immunotherapy as treatments for patients with melanoma.

A few years ago, the only two immune therapies that were approved for melanoma were interleukin-2 and interferon, Kluger says. Interferon has never been proven to prolong survival and interleukin-2 only prolongs survival in a small subset of patients.

About two years ago, Kluger says, ipilimumab was approved and is active in a majority of patients. Currently, there is a trial looking at the efficacy of adding a PD-1 inhibitor to ipilimumab. Kluger thinks that these two immune therapies may even be able to be used sequentially.

Kluger predicts that in the future, the first-, second-, and third-line therapy for patients with metastatic melanoma will be an immune-targeted therapy.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the effectiveness of immunotherapy as treatments for patients with melanoma.

A few years ago, the only two immune therapies that were approved for melanoma were interleukin-2 and interferon, Kluger says. Interferon has never been proven to prolong survival and interleukin-2 only prolongs survival in a small subset of patients.

About two years ago, Kluger says, ipilimumab was approved and is active in a majority of patients. Currently, there is a trial looking at the efficacy of adding a PD-1 inhibitor to ipilimumab. Kluger thinks that these two immune therapies may even be able to be used sequentially.

Kluger predicts that in the future, the first-, second-, and third-line therapy for patients with metastatic melanoma will be an immune-targeted therapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x